Company news
Quest PharmaTech Inc. news in 2020
Quest PharmaTech Inc.'s news releases, calls and decks from 2020, newest first.
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer
November 9, 2020
Quest Provides Corporate Update
June 4, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings
May 29, 2020
UPDATE - IIROC Trading Halt - QPT
May 4, 2020
Quest PharmaTech Announces Results from its April 28, 2020 AGM
May 1, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer
April 22, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer
March 24, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.
March 13, 2020